IPOs this week : April 27 - May 1, 20 (wk 18)

IPO quiet period expirations

• WiMi Hologram Cloud (NASDAQ:WIMI) on April 27 and 
• Zentalis Pharma (NASDAQ:ZNTL) on April 28. IPO share 

IPO lockup expirations

• Oyster Point (NASDAQ:OYST) and RAPT Therapeutics (NASDAQ:RAPT) on April 28. 

Amid the lack of new IPOs, the Renaissance IPO ETF (NYSEARCA:IPO) is still chugging along and is down only 3% YTD compared to a 12% decline in the S&P 500. Top performers for the ETF include Moderna (NASDAQ:MRNA), Zoom Video (NASDAQ:ZM) and Chewy (NYSE:CHWY).

IPOs this week : June 3 - 7, 19 (wk 23)

Analyst quiet period expirations: 

• Trevi Therapeutics (NASDAQ:TRVI), 
• Parsons (NYSE:PSN), 
• HeadHunter (NASDAQ:HHR), 
• Axcella Health (NASDAQ:AXLA), 
• NextCure (NASDAQ:NXTC), 
• Mayville Engineering (NYSE:MEC), 
• Milestone Pharma (NASDAQ:MIST), 
• South Plains Financial (NASDAQ:SPFI) and 
• Cortexyme (NASDAQ:CRTX) on June 3; 
• Sonim Technologies (NASDAQ:SONM) and 
• Jiayin (NASDAQ:JFIN) on June 4.

IPO share lockup expirations:

• Mogu (NYSE:MOGU) on June 4; 
• Moderna (NASDAQ:MRNA), 
• Synthorx (NASDAQ:THOR) and DiaMedica (NASDAQ:DMAC) on June 5.

MRNA : 2-month performance

Moderna (MRNA) : progress report on cancer treatments

• Moderna (MRNA) today announced recent progress updates in its immune-oncology and rare disease programs and highlighted corporate objectives for 2019-2020. Included among this presentation, Moderna highlighted that based on previously reported clinical observations in two patients with advanced ovarian carcinoma in a Phase 1 study, it has submitted an IND amendment to the FDA and to the study's clinical research sites to commence a Phase 2 cohort of mRNA-2416 (OX40L) as a monotherapy in advanced ovarian carcinoma within its current Phase 1 study. An IND application has also been submitted to the FDA for mRNA-3704, Moderna's development candidate for methylmalonic acidemia. Moderna noted that it expects its cash, cash equivalents, and investments in marketable securities as of December 31, 2018 to be approx. $1.7 bln, compared to $902 mln as of December 31, 2017.

Moderna (MRNA) began trading on the Nasdaq on 7 December 2018

Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA (mRNA). The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.
The pharma is shaping its mRNA platform into prophylactic and cancer vaccines, as well as immuno-oncology, regenerative and systemic therapeutics.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

Sector: Healthcare
Industry: Biotechnology
Headquarters: Cambridge, Massachusetts
Number of employees: ~700
Founded: 2010
http://www.modernatx.com

Offer size: $604 million; 21.7 million shares